Showing 41 - 60 results of 295 for search '"tyrosine kinases"', query time: 0.08s Refine Results
  1. 41
  2. 42

    A Simple Machine Learning-Based Quantitative Structure–Activity Relationship Model for Predicting pIC<sub>50</sub> Inhibition Values of FLT3 Tyrosine Kinase by Jackson J. Alcázar, Ignacio Sánchez, Cristian Merino, Bruno Monasterio, Gaspar Sajuria, Diego Miranda, Felipe Díaz, Paola R. Campodónico

    Published 2025-01-01
    “…<b>Background/Objectives:</b> Acute myeloid leukemia (AML) presents significant therapeutic challenges, particularly in cases driven by mutations in the FLT3 tyrosine kinase. This study aimed to develop a robust and user-friendly machine learning-based quantitative structure–activity relationship (QSAR) model to predict the inhibitory potency (pIC<sub>50</sub> values) of FLT3 inhibitors, addressing the limitations of previous models in dataset size, diversity, and predictive accuracy. …”
    Get full text
    Article
  3. 43
  4. 44

    REPEATED THERAPEUTIC LEUKAPHERESIS - A SOLE TREATMENT DURING PREGNANCY AS A BRIDGE BEFORE TYROSINE KINASE INHIBITORS FOR A PREGNANT WOMAN WITH CHRONIC MYELOGENOUS LEUKEMIA – A CASE REPORT AND DISCUSSION by Ivan Tonev, Chavdar Botev, Georgui Balatzenko, Milcho Mincheff

    Published 2025-01-01
    “…The mother achieved hematologic, cytogenetic and molecular remission within the next 6-9 months after initiation of tyrosine kinase inhibitor therapy. Discussion: The classical treatment for CML includes tyrosine kinase inhibitors, chemotherapy and/or allogeneic haematopoietic stem cell transplantation. …”
    Get full text
    Article
  5. 45

    Perbedaan Rerata Kadar Soluble Fms-Like Tyrosine Kinase-1 (Sflt-1) Serum pada Penderita Early Onset, Late Onset Preeklampsia Berat / Eklampsia dan Kehamilan Normal by Laila Rahmi, Rahmatina B. Herman, Yusrawati .

    Published 2016-01-01
    “…Kegagalan pengaturan dan ketidakseimbangan agen vasoaktif proangiogenik dan antiangiogenik plasenta, <em>soluble fms</em><em>-like tyrosine kinase</em>-1 (sFlt-1), <em>vascular endothelial growth factor</em> (VEGF) dan <em>placental growth factor</em> (PlGF) memainkan peran penting dalam patogenesis preeklampsia. …”
    Get full text
    Article
  6. 46

    Comparison of glycosylated fibronectin versus soluble fms-like tyrosine kinase/placental growth factor ratio testing for the assessment of pre-eclampsia: protocol for a multicentre diagnostic test accuracy study by Marcus Green, Chao Wang, Sarah Fisher, Amarnath Bhide, Ramesh Ganapathy, Basky Thilaganathan, Nouran Elbarbary

    Published 2025-02-01
    “…This study aimed to test the hypothesis that the sensitivity of the GlyFn test is not inferior to that of the current gold standard of soluble fms-like tyrosine kinase (sFlt)/PlGF-based laboratory testing for pre-eclampsia.Methods and analysis This is a multicentre prospective study. …”
    Get full text
    Article
  7. 47
  8. 48

    Different Activity of the Biological Axis VEGF-Flt-1 (fms-Like Tyrosine Kinase 1) and CXC Chemokines between Pulmonary Sarcoidosis and Idiopathic Pulmonary Fibrosis: A Bronchoalveolar Lavage Study by Katerina M. Antoniou, Giannoula Soufla, Athanasia Proklou, George Margaritopoulos, Christiana Choulaki, Rena Lymbouridou, Katerina D. Samara, Demetrios A. Spandidos, Nikolaos M. Siafakas

    Published 2009-01-01
    “…We estimated the levels of vascular endothelial growth factor (VEGF) and its high-affinity receptor, Flt-1 (fms-like tyrosine kinase 1), in bronchoalveolar lavage fluid (BALF) of patients with IPF and pulmonary sarcoidosis. …”
    Get full text
    Article
  9. 49
  10. 50
  11. 51
  12. 52
  13. 53
  14. 54
  15. 55

    Protocol for a multicentre randomised controlled trial examining the effects of temporarily pausing Bruton tyrosine kinase inhibitor therapy to coincide with SARS-CoV-2 vaccination and its impact on immune responses in patients with chronic lymphocytic leukaemia by Abhishek Abhishek, Jonathan A Cook, Helen M Parry, Anne Francis, Lelia Duley, Vicki S Barber, Paul Moss, Nicholas Peckham

    Published 2023-09-01
    “…This study aims to determine in patients with chronic lymphocytic leukaemia (CLL) if a 3-week pause in Bruton tyrosine kinase inhibitor therapy (BTKi) starting 1 week before delivery of SARS-CoV-2 vaccine booster, improves vaccine immune response when compared with continuation of BTKi.Methods and analysis An open-label, randomised controlled superiority trial will be conducted in haematology clinics in approximately 10 UK National Health Service (NHS) hospitals. …”
    Get full text
    Article
  16. 56
  17. 57
  18. 58
  19. 59
  20. 60